Patents by Inventor Diane Tribble
Diane Tribble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230137382Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: November 15, 2022Publication date: May 4, 2023Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Patent number: 11530410Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: September 25, 2020Date of Patent: December 20, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Publication number: 20210285003Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: September 25, 2020Publication date: September 16, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Patent number: 10858657Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: August 7, 2018Date of Patent: December 8, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Publication number: 20190071677Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: August 7, 2018Publication date: March 7, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Publication number: 20170342420Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: April 10, 2017Publication date: November 30, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
-
Patent number: 9650636Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: November 12, 2014Date of Patent: May 16, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Publication number: 20170096662Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.Type: ApplicationFiled: May 18, 2016Publication date: April 6, 2017Applicant: Kastle Therapeutics, LLCInventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
-
Patent number: 9347061Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.Type: GrantFiled: March 24, 2008Date of Patent: May 24, 2016Assignee: Genzyme CorporationInventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
-
Patent number: 9107933Abstract: Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III include compounds targeting Apolipoprotein B (ApoB) such as Mipomersen and other antisense compound targeting ApoB.Type: GrantFiled: March 16, 2010Date of Patent: August 18, 2015Assignees: Isis Pharmaceuticals, Inc., President and Fellows of Harvard CollegeInventors: Frank M. Sacks, Diane Tribble
-
Publication number: 20150167005Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: November 12, 2014Publication date: June 18, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Patent number: 8912160Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: January 10, 2014Date of Patent: December 16, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Andrew T. Watt, Diane Tribble
-
Publication number: 20140194492Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: January 10, 2014Publication date: July 10, 2014Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Patent number: 8664190Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: November 22, 2011Date of Patent: March 4, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Publication number: 20120129911Abstract: Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III include compounds targeting Apolipoprotein B (ApoB) such as Mipomersen and other antisense compound targeting ApoB.Type: ApplicationFiled: March 16, 2010Publication date: May 24, 2012Inventors: Frank M. Sacks, Diane Tribble
-
Publication number: 20120077865Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: November 22, 2011Publication date: March 29, 2012Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Patent number: 8093222Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: June 4, 2009Date of Patent: January 10, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Patent number: 8084437Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: GrantFiled: November 27, 2007Date of Patent: December 27, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
-
Publication number: 20100297105Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.Type: ApplicationFiled: March 24, 2008Publication date: November 25, 2010Applicant: GENZYME CORPORATIONInventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
-
Publication number: 20100144834Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.Type: ApplicationFiled: November 27, 2007Publication date: June 10, 2010Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina Lemonidis Tarbet, Sanjay Bhanot, Diane Tribble, Andrew T. Watts